Takeda Pharmaceutical Company Limited
Next Step in Transformation for Strengthening Competitiveness and Accelerating Future Growth
Aiming to achieve annualized cost savings exceeding 200 billion yen by fiscal year 2028, with approximately 150 billion yen in business restructuring expenses expected to be recorded in fiscal year 2026.
Key Figures
- Cost Reduction Effect: Over 200 billion yen on an annualized basis (through FY2028)
- Business Restructuring Expenses: Approximately 150 billion yen (projected for FY2026)
- Business Restructuring Expenses: Expected to be lower in FY2027 and FY2028 compared to FY2026
AI要約
Overview of the Transformation
Takeda Pharmaceutical Company Limited's Board of Directors approved an organizational restructuring aimed at strengthening competitiveness and enhancing long-term growth capabilities. The company expects cost savings exceeding 200 billion yen on an annualized basis by fiscal year 2028, promoting streamlining of corporate functions and process simplification through the utilization of advanced technologies. This plan is intended to absorb the costs required for new product launches and progressing late-stage development pipelines.
Expense Recognition and Future Outlook
Approximately 150 billion yen in business restructuring expenses is expected to be recorded in fiscal year 2026, and these costs will be reflected in the consolidated earnings guidance announced during the full-year financial results release for fiscal year 2025. Lower expenses than this are anticipated for fiscal years 2027 and 2028. These initiatives are considered to have minimal impact on the full-year consolidated earnings guidance for fiscal year 2025. Details and timing of individual measures will be decided going forward.
